Scientific Reports · 2018 · 32 citations · 48 references
MedicineMedicinal ChemistryOncologyBiomedical ImagingMolecular ImagingMolecular OncologyBreast Cancer ImagingHer2-positive Breast CancerMolecular Probe DevelopmentReceptor ImagingTargeted Imaging AgentsTumor ImagingAntibodiesHer2 ExpressionHer2 Targeting LigandsMolecular Imaging TracersPeptide Ligand DiscoveryPeptide Targeting LigandsPeptide-based Imaging AgentsReceptor-targeted Imaging Agents
Abstract HER2 transmembrane receptor is an important target in immunotherapy treatment of breast and gastroesophageal cancer. Molecular imaging of HER2 expression may provide essential prognostic and predictive information concerning disseminated cancer and aid in selection of an optimal therapy. Radiolabeled low molecular weight peptide ligands are particularly attractive as probes for molecular imaging, since they reach and bind to the target and clear from non-target organs and blood stream faster than bulky antibodies. In this study, we evaluated a potential HER2-imaging probe, an A9 nonapeptide, derived from the trastuzumab-Fab portion. Its cellular uptake was investigated by mass spectrometry analysis of the cytoplasmic cellular extracts. Moreover, based on in-silico modeling, DTPA chelator was conjugated to N-terminus of A9. 111 In-labeled A9 demonstrated nanomolar affinity to HER2-expressing BT474 cells and favorable biodistribution profile in NMRI mice. This study suggests that the peptide A9 represents a good lead candidate for development of molecular probe, to be used for imaging purposes and for the delivery of cytotoxic agents.
48
Dennis J. Slamon, Gary M. Clark, Steven Wong et al. · Science · 1987 · 11.7K citations
Michael A. Bookman, Kathleen M. Darcy, Daniel L. Clarke‐Pearson et al. · Journal of Clinical Oncology · 2003 · 613 citations
Medicine, Gynecology, Oncology +17